Ergomed logo

ERGO - Ergomed News Story

686p -4.0  -0.6%

Last Trade - 8:38am

Sector
Healthcare
Size
Small Cap
Market Cap £334.0m
Enterprise Value £325.2m
Revenue £68.3m
Position in Universe 625th / 1807

Ergomed plc - Results of 2018 Annual General Meeting

Tue 12th June, 2018 3:55pm
RNS Number : 1645R
Ergomed plc
12 June 2018
 

PRESS RELEASE

FOR IMMEDIATE RELEASE

 

 

Results of 2018 Annual General Meeting

 

London, UK - 12 June 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that all resolutions put to shareholders were duly passed at its Annual General Meeting held earlier today.

 

Resolutions 1 to 5 were passed on a show of hands.

 

Details of proxy results were as follows:

 

Resolution number

Votes for

Votes against

Abstentions

1

21,318,347

Nil

Nil

2

21,317,894

Nil

453

3

21,317,894

Nil

453

4

19,056,035

Nil

2,262,312

5

21,317,894

Nil

453

 

Details of voting results for resolutions 6 and 7 (including proxies) were as follows:

 

Resolution number

Votes for

Votes against

Abstentions

6

30,158,064

2,351,500

520

7

25,689,064

6,820,500

520

 

The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com

 

ENDS

 

 

 

 

 

Enquiries:

 

Ergomed plc

   Tel: +44 (0) 1483 503205

Stephen Stamp (Chief Executive Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)


James Black (Joint Broker)




N+1 Singer

Tel: +44 (0) 20 7496 3000

Aubrey Powell (Joint Broker)




Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Ivar Milligan / Philippa Gardner




MC Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke


 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGEALKAFSDPEFF
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.